This phase 2 , 12-week , randomized , double-blind , placebo-controlled parallel-group study of tiotropium Respimat as add-on to usual cystic fibrosis maintenance therapy included people with cystic fibrosis with pre-bronchodilator forced expiratory volume in 1 second ( FEV1 ) 25 % predicted .